

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



Sinopharm Tech Holdings Limited **國藥科技股份有限公司**

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)

INSIDE INFORMATION **UPDATE ON THE CONVERTIBLE BONDS**

This announcement is made by Sinopharm Tech Holdings Limited (the “**Company**”) pursuant to Rule 17.10(2) and Rule 17.21 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the announcements (the “**Announcements**”) of the Company dated 13 January 2014, 17 January 2014, 18 January 2017, 18 January 2018, 17 January 2019, 7 February 2020 and 19 January 2021 in relation to the issue of the Convertible Bonds with a principal amount of HK\$89,625,000 by the Company. Unless the context requires otherwise, capitalized terms used herein but not otherwise defined shall have the same meanings as those given to them in the Announcements.

Pursuant to the Fifth Amendment Agreement, the Convertible Bonds was due on 17 January 2022 (the “**Maturity Date**”). Pursuant to the Subscription Agreement (as amended by the Fifth Amendment Agreement), the Bondholder may exercise its right to convert any Convertible Bonds at any time during the Conversion Period, or the Company may redeem the Convertible Bonds before the Maturity Date.

As at the date of this announcement, the principal amount of HK\$89,625,000 remained outstanding for redemption by the Company as neither did the Bondholder (being Integrated Asset Management) exercise any conversion right attaching to the Convertible Bonds, nor did the Company redeem any part of the Convertible Bonds. Pursuant to the terms and conditions in the Subscription Agreement and of the Convertible Bonds, it constitutes an event of default

if, among others, the Company fails to pay any amount due on Interest Payment Dates and at the Maturity Date (provided that the Company shall have 5 business days to remedy such breach). In case of an event of default, the Bondholder is entitled to give notice to the Company that the outstanding amounts under the Convertible Bonds are immediately due and payable.

As at the date of this announcement, the Company has not received any notice of event of default from the Bondholder demanding immediate repayment nor notice of exercise of the Convertible Bonds.

The Company will negotiate with the Bondholder for the renewal of or further extension on the Convertible Bonds and disclose further developments on the above matters by way of further announcement(s) in a timely manner in accordance with regulatory requirements.

Shareholders and potential investors of the Company should note that the inability of the Company to fully redeem the Convertible Bonds in the event of its failure to renew and refinance the Convertible Bonds with the Bondholder shall trigger a default on the Convertible Bonds. Accordingly, shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By Order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Chairperson

Hong Kong, 18 January 2022

As at the date of this announcement, the Board comprises Mr. CHAN Ting, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Madam CHEUNG Kwai Lan and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.